Essential Medicines in Africa: The Unaddressed Pharmacogenomic Frontier
A new analysis of the World Health Organization and 52 African national Essential Medicines Lists (EMLs) reveals a critical gap: these lists, which guide treatment for millions, currently do not account for pharmacogenomics. The study identifies that 13% of medicines on the WHO list, and on average one in eight medicines on African national lists, have actionable pharmacogenomic biomarkers that could predict efficacy or safety. This oversight is particularly significant for a continent representing more genetic variation than the rest of the world combined, where standard dosing may lead to suboptimal outcomes for key drug classes like anti-infectives.
Continue reading to unlock the full analysis, deeper implications, and why this study may matter for your field.
Unlock Full Briefing — 50% Off with Coupon: ERWMCWYU
Full version includes the complete summary, study significance, and direct link to the original source.
Stay curious. Stay informed — with Science Briefing.
This is a preview briefing. Upgrade to access the full version.
